HHS RULING

HHS secretary overrules FDA on widening availability of Plan B drug

Levonorgestrel (Plan B One-Step, Teva Pharmaceuticals) will remain available by prescription only to adolescents aged 16 years and younger after the Health and Human Services secretary overruled FDA’s recommendation to allow the emergency contraceptive to be sold over the counter for this age group. » More

CONTINUING EDUCATION

Pre-diabetes and type 2 diabetes management

With 25.8 million Americans diagnosed with diabetes and an estimated 79 million more pre-diabetic, every pharmacist must be able to counsel patients and monitor progression. Earn up to 2 CPE credits. » Click here to login and take the exams.

LEGAL NEWS

Opposition to ESI/Medco merger is expressed at Senate hearing

Pharmacy chains and organizations continue to actively oppose the merger of Express Scripts Inc. and Medco Health Solutions. » More

Harness the Power of Social Media to Build Your Business

Digital communication makes it easier than ever to stay connected to your customers. Learn more about connecting to your customers to generate store traffic.
Go to: KeepYourPharmacyOpen.com.

Survey

President Obama’s executive order to take action on the public health crisis of prescription drug shortages includes directing FDA to broaden reporting of potential shortages, expedite regulatory reviews, and increase staffing resources for the FDA’s Drug Shortages Program. Do you agree with his executive order?

a) Yes, it will definitely make a difference to the prescription drug shortages.
b) Yes, but it will take more than the order to fix the prescription drug shortages.
c) No, Congress should be enacting legislation to fix the prescription drug shortages.
d) No, the order will do little to help the prescription drug shortages.

Respond here and see what your colleagues think too.

Want to see the results of our last survey about the implications of the possible Express Scripts/Medco merger? Click here.

FDA ACTIONS

New formulation of extended-release opioid to be crush resistant

FDA approved a "crush-resistant" formulation of oxymorphone extended release (Opana ER, Endo Pharmaceuticals) with the intent to help patients with appropriate use of opioids. » More

U.S. Marshals seize Syntec dietary supplements

U.S. Marshals recently seized all dietary supplements manufactured by Syntec Inc. for false claims made by the company about the products’ safety and effectiveness in treating various diseases. » More

FDA, FTC act to remove HCG weight-loss products from market

FDA and the Federal Trade Commission have sent warning letters to several companies that are marketing homeopathic human chorionic gonadotropin products for weight loss.
» More

CLINICAL NEWS

Ranbaxy launches generic Caduet

Ranbaxy has launched an authorized generic version of Caduet in the U.S. market, as part of an agreement with Pfizer. » More

Teva introduces authorized generic birth-control pill

Teva Pharmaceuticals announced in a prepared statement that levonorgestrel/ethinyl estradiol and ethinyl estradiol tablets (Camrese Lo) are now available. » More

Confirm your
e-newsletter subscription click here.

To ensure future delivery of email newsletters from Drug Topics please take a moment to confirm your subscription by clicking here.
Thank you,
Drug Topics Staff

Voices

•	DT Blog
•	JP at Large
•	View from the Zoo
•	Viewpoints
•	Regulatory & Legal

Meetings & Events

Digital Edition

•	View current edition

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.